First Tracks Biotherapeutics (TRAX) — Strategic Asset Allocation Index
First Tracks Biotherapeutics (TRAX) has a Strategic Asset Allocation Index of 9.1% as of December 2024. Strategic assets (PP&E of $- plus long-term investments of $35.47 Million) total $35.47 Million, measured against net assets of $391.60 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check TRAX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
First Tracks Biotherapeutics Strategic Asset Allocation Index (2023–2024)
This chart shows how First Tracks Biotherapeutics's Strategic Asset Allocation Index has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the index stands at 9.1%, representing strategic assets of $35.47 Million against net assets of $391.60 Million USD. See TRAX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for First Tracks Biotherapeutics (2023–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for First Tracks Biotherapeutics from 2023 to 2024, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of First Tracks Biotherapeutics.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 9.1% | $35.47 Million | $- | $35.47 Million | $391.60 Million | ▲ +2.5 pp |
| 2023 | 6.6% | $27.03 Million | $- | $27.03 Million | $409.85 Million | — |